The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Washington

Dana-farber-cancer Institute Inc.

Leland Stanford Junior University

University of Pennsylvania

Duke University

The Scripps Research Institute

Boston University

International Aids Vaccine Initiative

Institute for Research in Biomedicine

Los Alamos National Security, LLC

Triad National Security, LLC

Sanofi

The United States of America, As Represented by the Secretary, Departmen

Tongqing Zhou

Peter D Kwong

John R Mascola

Baoshan Zhang

Gwo-Yu Chuang

Gary J Nabel

Yongping Yang

Zhi-yong Yang

Ivelin Georgiev

Mark Connors

Xueling Wu

Michael Gordon Joyce

Guillaume Stewart-Jones

Richard Wyatt

Marie Pancera

Barney S Graham

Cheng Cheng

Jason Scott McLellan

Aliaksandr Druz

Man Chen

Wing-Pui Kong

William Ray Schief

Li Ou

Joseph G Sodroski

Masaru Kanekiyo

Jeffrey C Boyington

John Mascola

Young Do Kwon

Wei Shi

Ling Xu

Gilad Ofek

Barton F Haynes

Antonio Lanzavecchia

Dennis R Burton

Davide Corti

Huawei Qiu

Hua-Xin Liao

Bette T Korber

Wayne C Koff

Sanjay K Phogat

Ercole Rao

Beatrice H Hahn

Christian Lange

George M Shaw

Jochen Kruip

Pascal Raymond Georges Poignard

Melissa Danielle De Jean De St Marcel Simek-Lemos

Christian Beil

Jason Gorman

Mallika Sastry

Mario Roederer

Yuxing Li

Kai Xu

Rebecca S Rudicell

Cinque Soto

Zhi-Yong Yang

Jochen Beninga

Wulf Dirk Leuschner

Carl-Magnus Hogerkorp

Jiang Zhu

Barna Dey

Lei Chen

Priyamvada Acharya

Rita Chen

Wen Yuan

Shi-Hua Xiang

Sanjay Srivatsan

Rebecca M Lynch

Feng Gao

Yaroslav Tsybovsky

Jinghe Huang

Thomas B Kepler

Paul Thomas

Scott D Boyd

Byong Ha Kang

Elise Ishida

Anqi Zheng

Rui Kong

Kevin Liu

Ulrich Baxa

Wing-pui Kong

Melissa Danielle De Jean St Marcel Simek-Lemos

Lawrence Shapiro

Mangaiarkarasi Asokan

Amarendra Pegu

Chih-Chin Huang

Richard A Koup

William R Schief

Gary Nabel

Nicole A Doria-rose

Ronnie Wei

Peter Kwong

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 ENV fusion peptide immunogens and their use

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

Neutralizing antibodies to GP120 and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Prefusion RSV F proteins and their use

HIV-1 Env fusion peptide immunogens and their use

Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.

The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).

Antibody evolution immunogens

Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.

Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

Neutralizing antibodies to gp120 and their use

Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein

Growing community of inventors

Boyds, MD, United States of America

Tongqing Zhou